Clinical trials: Hematopoietic Neoplasms
Diffuse Large B Cell Lymphoma
Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy
This is a prospective, single-arm, open study to observe the efficacy and safety of the CART-SCB regimen (Clinical Regimen for the Prospective Study of Autologous Hematopoietic Stem Cell Boost for the Improvement of Bone Marrow…
- Trial name
- NCT06589089
- Testing
- autologous hematopoietic stem cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Ruijin Hospital
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Biomarkers to Predict Cancer Therapy-related Cardiotoxicity
This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.
- Trial name
- NCT06353191
- Testing
- Non-Interventional Study
- Where
- 4 sites in United States
- Volunteers
- 693 people
- Sponsor
- Mayo Clinic
Solid Tumor Malignancies, Hematologic Cancer
The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
The purpose of this study is to explore the effectiveness of 18F-G1 PET/CT in patients with solid tumors and hematological malignancies receiving immunotherapy
- Conditions
- Solid Tumor Malignancies, Hematologic Cancer, Lung Cancer, Esophagus Cancer
- Trial name
- NCT07039474
- Testing
- 18F-G1
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Vitamin A and D Supplementation in Allogeneic HCT
The therapy under investigation is the addition of 300 000 IU of vitamin A and 100 000 IU of vitamin D before conditioning. The study will include patients with malignant diseases in hematologic response with indications for…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma
- Trial name
- VitaStem (NCT06508099)
- Testing
- Vitamin A, Vitamin D3
- Where
- Russia
- Volunteers
- 220 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Hematologic Malignancies, Nonmalignant Diseases
Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation
Fludarabine is a chemotherapy drug used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of fludarabine in their bodies and if drug…
- Conditions
- Hematologic Malignancies, Nonmalignant Diseases, Immunodeficiencies, Hemoglobinopathies
- Trial name
- HCT (NCT01316549)
- Testing
- Fludarabine
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of California, San Francisco
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Evaluating Clinical Evaluation Tools for Predicting Risk of Complications After Hematopoietic Stem Cell Transplant
This study evaluates whether clinical evaluation tools such as the six-minute walk test, hand grip strength test, and gait speed test, are useful in predicting risk of complications in patients undergoing hematopoietic stem cell…
- Trial name
- NCT05766332
- Testing
- Clinical Evaluation, Electronic Health Record Review
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Mayo Clinic
Hematologic Cancer
Virtual Reality Intervention to Improve Comfort in Hospitalized Hematology Patients
The objective of this clinical trial is to determine whether virtual reality (VR) devices can improve comfort and quality of life in hospitalized adult patients with hematological malignancies who require at least 15 consecutive…
- Trial name
- NCT07894601
- Testing
- Immersive virtual reality experience
- Where
- 2 sites in Spain
- Volunteers
- 145 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Myeloproliferative Disorders, Leukemia
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00827099
- Testing
- anti-thymocyte globulin, fludarabine phosphate, Melphalan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Northside Hospital, Inc.
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer
RATIONALE: Giving chemotherapy drugs, such as busulfan and etoposide, and intensity-modulated radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Trial name
- NCT00540995
- Testing
- busulfan, etoposide, intensity-modulated radiation therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to test the safety of specialized white cells from the donor at different doses. They are called WT1 sensitized T cells. They have been grown in the lab and are immunized against a protein.
- Trial name
- NCT01758328
- Testing
- busulfan, melphalan, fludarabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia
This multicenter, prospective phase III-study is to compare the administration of ATG FRESENIUS to the NON-administration of ATG FRESENIUS in a myeloablative conditioning regimen followed by allogeneic hematopoeitic stem cell…
- Trial name
- NCT00678275
- Testing
- ATG FRESENIUS (Anti-Lymphocyte-Globulin)
- Where
- Germany
- Volunteers
- 161 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Malignant Neoplasm
Early Oral Supplementation in Improving Nutritional Status in Patients Undergoing Hematopoietic Stem Cell Transplant
This clinical trial studies the use of early oral supplementation in improving nutritional status in participants undergoing hematopoietic stem cell transplant.
- Trial name
- NCT02590107
- Testing
- Boost Plus, Pro-Stat 101, Milkshake
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Aromatherapy Oil Associated for Managing Anxiety and Pain During Bone Marrow Biopsy Procedures
This clinical trial evaluates whether using aromatherapy can reduce pain and anxiety for cancer patients during routine biopsy procedures.
- Trial name
- NCT06581211
- Testing
- Aromatherapy and Essential Oils, Electronic Health Record Review, Jojoba Oil
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- City of Hope Medical Center
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Evaluation of Satisfaction With Quality of Care on the Palliative Care Unit
This study examines the difference between the quality of care patients receive with palliative care consult services and the palliative care unit.
- Trial name
- NCT02686411
- Testing
- Survey Administration
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
This phase II trial studies how well giving siltuximab during the reintroduction (rechallenge) of immune checkpoint inhibitor (ICI) therapy works in preventing severe immune-related adverse events (irAEs) in patients with cancer…
- Trial name
- NCT06470971
- Testing
- Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Biopsy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Yuanquan Yang
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
This phase II MATCH treatment trial identifies the effects of GDC-0032 (taselisib) in patients whose cancer has a genetic change called PIK3CA mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439175
- Testing
- Taselisib
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Neoplasm
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
This phase I/Ib trial studies the side effects and best dose of ipilimumab or nivolumab in treating patients with cancers of the blood and blood-forming tissues (hematologic cancers) that have returned after a period of…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT01822509
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 13 sites in United States
- Volunteers
- 71 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed Acute Myeloid Leukemia
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
The investigators hypothesize that flotetuzumab for relapsed AML following allo-HCT will be safe, tolerable and may facilitate preferential immune effector cell retargeting of leukemic cells resulting in improved patient…
- Trial name
- NCT04582864
- Testing
- Flotetuzumab, Donor lymphocyte infusion
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Washington University School of Medicine
Hematological Malignancies, Leukemia
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
This research study uses a drug called cyclophosphamide to decrease the incidence of GVHD in matched sibling hematopoietic stem cell transplant. In doing so, the goal of the study is to increase overall survival.
- Conditions
- Hematological Malignancies, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT01315132
- Testing
- Matched Sibling Allogeneic Transplantation
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hematopoietic and Lymphoid System Neoplasm, Malignant Breast Neoplasm
Use of Virtual Reality Goggles During Chemotherapy Infusion to Reduce Anxiety-Related Symptoms
This clinical trial evaluates the use of virtual reality (VR) goggles during chemotherapy infusion to reduce anxiety-related symptoms in patients with head and neck, thoracic, hematologic, and breast cancers.
- Conditions
- Hematopoietic and Lymphoid System Neoplasm, Malignant Breast Neoplasm, Malignant Head and Neck Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT05793957
- Testing
- Questionnaire Administration, Telephone-Based Intervention, Virtual Technology Intervention
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- OHSU Knight Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.